The discovery of the BCR-ABL1 fusion oncogene has facilitated the development of specific targeted therapies for CML patients, blocking tyrosine kinase activity. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.